Bank of America Corp DE Purchases 235,493 Shares of Roivant Sciences Ltd. $ROIV

Bank of America Corp DE increased its position in Roivant Sciences Ltd. (NASDAQ:ROIV) by 8.0% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,163,821 shares of the company’s stock after buying an additional 235,493 shares during the quarter. Bank of America Corp DE’s holdings in Roivant Sciences were worth $87,638,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in ROIV. SBI Securities Co. Ltd. grew its holdings in Roivant Sciences by 1,740.3% during the 4th quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock worth $27,000 after acquiring an additional 1,166 shares during the last quarter. Allworth Financial LP increased its position in Roivant Sciences by 48.1% in the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock valued at $27,000 after acquiring an additional 583 shares during the period. Kestra Advisory Services LLC bought a new position in shares of Roivant Sciences during the fourth quarter valued at $47,000. Parallel Advisors LLC raised its stake in shares of Roivant Sciences by 33.7% during the first quarter. Parallel Advisors LLC now owns 2,065 shares of the company’s stock valued at $57,000 after acquiring an additional 520 shares during the last quarter. Finally, CIBC Private Wealth Group LLC raised its stake in shares of Roivant Sciences by 7,614.3% during the fourth quarter. CIBC Private Wealth Group LLC now owns 2,700 shares of the company’s stock valued at $59,000 after acquiring an additional 2,665 shares during the last quarter. Institutional investors own 64.76% of the company’s stock.

Insider Activity at Roivant Sciences

In other news, Director Daniel Allen Gold sold 800,000 shares of Roivant Sciences stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $34.55, for a total value of $27,640,000.00. Following the completion of the transaction, the director directly owned 13,701,546 shares of the company’s stock, valued at approximately $473,388,414.30. This trade represents a 5.52% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Eric Venker sold 200,000 shares of the business’s stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $33.16, for a total value of $6,632,000.00. Following the completion of the transaction, the chief executive officer directly owned 1,613,063 shares in the company, valued at $53,489,169.08. This represents a 11.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 2,055,913 shares of company stock worth $69,639,633 over the last quarter. Company insiders own 8.80% of the company’s stock.

Roivant Sciences Stock Performance

Shares of NASDAQ ROIV opened at $36.34 on Friday. The company has a market capitalization of $26.14 billion, a P/E ratio of -68.57 and a beta of 1.12. Roivant Sciences Ltd. has a 52-week low of $10.90 and a 52-week high of $37.00. The company’s 50 day moving average price is $33.13 and its 200-day moving average price is $29.46.

Roivant Sciences News Roundup

Here are the key news stories impacting Roivant Sciences this week:

• Positive Sentiment: Guggenheim raised its price target to $42 from $36 and assigned a “Buy” rating. The revision implies meaningful upside and provides a clear near-term bullish catalyst for Roivant Sciences (ROIV). Benzinga analyst upgrade
• Positive Sentiment: Roivant said it expects to launch brepocitinib for dermatomyositis by the end of September, a milestone that could improve confidence in the company’s commercialization strategy. It also plans to target cutaneous sarcoidosis, with Phase 3 data expected in 2028. Brepocitinib launch and pipeline update
• Positive Sentiment: Roivant’s subsidiary Immunovant reported that IMVT-1402 development remains on schedule across several autoimmune indications, including Graves’ disease and myasthenia gravis. Its cash balance is expected to fund operations through a potential Graves’ disease launch, reducing near-term financing concerns. Immunovant corporate update

Analysts Set New Price Targets

Several analysts recently weighed in on ROIV shares. Citigroup boosted their price objective on shares of Roivant Sciences from $35.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, May 21st. Sanford C. Bernstein raised Roivant Sciences to a “strong-buy” rating in a research report on Wednesday, July 29th. HC Wainwright lifted their target price on Roivant Sciences from $34.00 to $41.00 and gave the stock a “buy” rating in a report on Friday. Guggenheim upped their price target on Roivant Sciences from $36.00 to $42.00 and gave the company a “buy” rating in a research report on Friday. Finally, Piper Sandler reissued an “overweight” rating on shares of Roivant Sciences in a research note on Thursday, May 21st. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $34.77.

Roivant Sciences Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.